INVA

INVA is staging a high-conviction breakout (+2.93%) on 2.1x volume, driven by institutional positioning ahead of its Q4 earnings (Feb 25, 2026). The move reflects a 'Flight to Quality' rotation where capital is seeking the safety of INVA's robust GSK royalty cash flows combined with the growth optionality of the recently approved **Nuzolvence** (zoliflodacin). In a Neutral rate regime, INVA's profitable, non-speculative profile makes it a prime target for funds rotating out of long-duration tech.